potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus)

There's now concern about a potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus).

FDA is adding a black box warning...and will soon require you to give a Medication Guide to patients getting these drugs.

It's NOT known for sure if these drugs increase cancer risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote